Business Context and Reporting Period
Niagen Bioscience, Inc. (NAGE) filed this Form 8-K on June 24, 2026, to report the results of its 2026 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report regarding corporate governance matters and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals submitted to shareholders:
- Proposal 1 (Election of Directors): All eight nominees were elected. However, significant dissent was recorded for two directors: Steven Rubin received approximately 37% of votes withheld (16,796,230), and Hamed Shahbazi received approximately 33% of votes withheld (14,747,291). The remaining six directors received less than 5% of votes withheld.
- Proposal 2 (Ratification of Auditors): Shareholders approved the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 56,152,066 votes for and 2,256,090 votes against.
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation was approved with 43,188,958 votes for and 1,930,441 votes against.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting results.
Investor Verification Checklist
- Verify the reasons for the high percentage of votes withheld for directors Steven Rubin and Hamed Shahbazi.
- Confirm the company's financial status and liquidity position in the most recent 10-K or 10-Q filing, as this 8-K does not provide financial data.
- Review the company's proxy statement for the 2026 Annual Meeting to understand the context of the director elections and executive compensation vote.